Latest Kaiser Health News Stories
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
Several public health officials endorse using a federal law to slash hepatitis C drug prices in Louisiana and avoid drug bills that could cripple the state budget.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.